In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
26 authors.
Jordi Guillem-MartiBiomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Barcelona, Spain.ORCID 0000-0003-0307-2221 Daniel Cabrerizo-AguadoBiomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Barcelona, Spain.
Kevin Alexander Estrada AlamoDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-3829-357X Irina KopyevaDepartment of Bioengineering, University of Washington, Seattle, WA, USA.
Jing LiProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Yuxin HaoProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Aritza Brizuela-VelascoDENS-ia Research Group, Faculty of Health Sciences, Miguel de Cervantes European University, Valladolid, Spain.ORCID 0000-0001-6421-3863 Analisa MurrayDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Stacey GerbenDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Timothy SpringerProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-6627-2904 Hannele Ruohola-BakerOral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-5588-4531 Jose Maria ManeroBiomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Barcelona, Spain.ORCID 0000-0002-1673-4389 Maria-Pau GinebraBiomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering, Universitat Politècnica de Catalunya - BarcelonaTech (UPC), Barcelona, Spain.ORCID 0000-0002-4700-5621 Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MInterdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7MComprehensive Training in Inter-Disciplinary Oral Health ResearchT90DE021984 · NIDCR · UNIVERSITY OF WASHINGTON · PI Robert Aaron Cornell · 2012 to 2026
$7.9MStructures and Conformational Equilibria of Integrin alpha5 beta1R01HL131729 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI SPRINGER, TIMOTHY A · 2016 to 2024
$4.7MRegulation of cell migration and signaling by phosphotyrosine and ubiquitinR01GM109463 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COOPER, JONATHAN A · 2014 to 2022
$3.0MMimicking, Exploiting, and Understanding Biology's Heterogeneity in 4DR35GM138036 · NIGMS · UNIVERSITY OF WASHINGTON · PI Cole A DeForest · 2020 to 2026
$2.3MThe Molecular Basis for Integrin-Mediated Bidirectional SignalingR35GM147414 · NIGMS · FRED HUTCHINSON CANCER CENTER · PI Melody G Campbell · 2022 to 2026
$2.2MNCI NIH HHS P30 CA015704NCI NIH HHS T32 CA080416NHLBI NIH HHS R01 HL131729NIDCR NIH HHS T90 DE021984NIGMS NIH HHS R01 GM109463NIGMS NIH HHS R35 GM138036NIGMS NIH HHS R35 GM147414
6 · The paper itselfAbstract
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins could have considerable utility in regenerative medicine and next-generation therapeutics. We use computational protein design to create de novo α5β1-specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin and RGD peptide in enhancing cell attachment and spreading, and NeoNectin-grafted titanium implants outperformed fibronectin and RGD-grafted implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine.
Indexed as
biomaterialDe novo protein designhydrogelintegrin α5β1regenerative medicineRGDtitanium
Identifiers
PMID38979380
PMCPMC11230231
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390